Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

May 11, 2011

Navigating through the complex web of clinical trials

Author(s):

Debu Tripathy

Our stories and blogs about new treatments invariably raise questions that pertain to different clinical situations being experienced by our readers. Would this new treatment apply to my condition? How would I get access to this new drug through a clinical trial? The answer is complicated.The determination of who qualifies for an experimental trial, known as "eligibility criteria," can look like a series of roadblocks based on the stage of disease, prior therapies and a long list of blood tests that must return in a certain range. Some of the criteria are becoming even more complex because trials are being designed more from a biological standpoint. In fact, some trials are now addressing a particular gene mutation as opposed to a type of tumor. The rationale for this is that biology may trump the tissue of origin – we are getting more clues every year about specific tumor alterations that make them sensitive or resistant to targeted drugs. Also, genetic testing of tumors has become routine and quick.This trend is also spilling into clinical practice as newer gene and protein tests are becoming commercially available. In some cases, these test are being used "ahead of the data," or in other words, before we have definitive proof that a given treatment indicated by the test is really better that standard treatment. Imagine that a case of breast cancer that has not responded to the usual hormonal and chemotherapeutic drugs is found to express a protein found in gastrointestinal sarcoma tumor (GIST), which responds to the chronic myelogenous leukemia drug Gleevec. There are really no studies to verify that this strategy would work, but it certainly is very appealing. According to most guidelines, there are very few genetic tests that are actually "approved" as being proven to help with treatment decisions. Even BRCA testing for the breast and ovarian cancer susceptibility gene is not currently used to choose drugs in patients with cancer, but it is, of course being used to identify high-risk patients who need enhanced surveillance or even preventive surgery. For clinical trials, however, BRCA testing in patients with cancer is being used for some PARP inhibitor trials based on the biology of these drugs, which appear to inhibit DNA repair. These drugs might be more effective in patients who carry mutations in BRCA, which impairs DNA repair and might therefore predict extreme sensitivity to PARP inhibitors. However, we don't yet know that PARP inhibitors work only in BRCA-deficient cells, so this whole approach is investigational. So how is one in general supposed to navigate the complex web of choosing trials and knowing if one is eligible in the first place? CURE offers some resources to help with clinical trials, and websites are becoming better as search tools, such as www.clinicaltrials.org or www.breastcancertrials.org (specifically for breast cancer). You can search through various clinical trial websites in our Toolbox listing. You can also review our Patient's Guide to Clinical Trials for more information.It is probably not helpful to have unapproved protein or genetic tests performed on your tumor unless it is being done as part of a clinical trial to test for eligibility. However, it is very likely that newer tests will become more widely available and useful in the very near future.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content
Advertisement
The FDA approved Zegfrovy for advanced NSCLC with EGFR exon 20 mutations after chemotherapy: stock.adobe.com.
July 2nd 2025

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Spencer Feldman
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Image of Valarie with text.
July 2nd 2025

Living After Cancer: A Cancer Thriver Shares Her Story

Ryan Scott
Valarie Traynham, a cancer thriver and patient advocate, imparts advice and discusses survivorship after a cancer diagnosis.
Related Content
Advertisement
The FDA approved Zegfrovy for advanced NSCLC with EGFR exon 20 mutations after chemotherapy: stock.adobe.com.
July 2nd 2025

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Spencer Feldman
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Image of Valarie with text.
July 2nd 2025

Living After Cancer: A Cancer Thriver Shares Her Story

Ryan Scott
Valarie Traynham, a cancer thriver and patient advocate, imparts advice and discusses survivorship after a cancer diagnosis.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.